Connect with us

Opinion

Trends and expectations for the fertility sector in 2023

By Eran Eshed, CEO and co-founder of Fairtility

Published

on

Eran Eshed

2022 featured some pivotal moments whose impacts will reverberate into the new year. Eran Eshed, CEO and co-founder of Fairtility, reflects on the developments poised to shape fertility care in 2023.

This year, we saw the US Supreme Court overturn Roe v Wade in a decision with passionate responses from both sides of the political aisle. Through 2022, we have started to learn to live alongside Covid.

From a technological perspective, AI has clearly entered the Zeitgeist with endless social media posts featuring AI-generated art and text, stoking both excitement and fear of how AI will impact our future lives. And, we are facing a global economic downturn that is impacting people around the world with spiking rates of inflation and rising cost of living globally.

With these new realities in play, the field of fertility care will feel the effects of all of these trends in different, but significant ways. Let’s take a look at how some of 2022’s pivotal developments are poised to shape fertility care in 2023.

Roe v Wade and IVF Clinics in 2023

The overturning of Roe v Wade by the US Supreme may have a significant impact on IVF in 2023, specifically in states that do not explicitly allow for IVF or IVF embryo selection as part of their anti-abortion laws.

With state-by-state laws forming in the coming year, prospective parents will need to remain informed of their local legislation, as reproductive medical procedures may be restricted or entirely banned in certain states.

Consequently, prospective parents may need to travel out of state to receive IVF treatment. IVF clinics will have an uncertain year ahead as patient demand remains unpredictable in the wake of Roe v Wade.

Additionally, clinical IVF teams will need to remain vigilant as “foetal personhood” legislation, which suggests that foetuses and embryos have the same legal standing as a born child, may expose routine assisted reproductive technology procedures such as IVF to risk, and potential liability for providers.

IVF in the post-pandemic world requires innovation

We are seeing the impact today of healthcare treatment delays that occurred as a result of Covid. For prospective parents who are up against a biological clock, fertility treatment delays were agonizing. During the pandemic, many IVF clinics had to temporarily close the doors to patients.

As the world resettles into new routines alongside peeks and dips of Covid cases, patient demand for IVF is higher than ever.

However, filling this need is not simple as we face a global shortage of embryologists. Meeting this need requires the advancement of IVF technology to automate routine processes for clinicians, freeing up their time to service additional patients.

Digital transformation in this field will gain further momentum in 2023, as the introduction of new technologies into IVF clinics, such as AI-guided decision support tools, will help increase capacity, reduce costs, and improve access to reproductive health treatments.

The new generation of fertility patients are tech savvy

AI has entered our daily lives. This couldn’t be clearer as our social feeds are filled with ChatGPT and AI-generated portraits.

These new technological opportunities, combined with a younger generation that has grown up with endless access to information means today’s fertility patients are looking for greater automation, transparency and explainability in their care journey. This tech savvy generation wants to feel engaged and in control of their journey and choices.

Opportunity comes up against reality when prospective patients are sitting with their fertility specialists. The worst thing for prospective parents undergoing IVF to hear – other than the simple fact of an embryo transfer not implanting – is that there is no explanation for the failed attempt.

This can make patients feel they are sitting in the back seat of their treatments rather than in the driver’s seat.

Herein lies the opening where new AI solutions will have an impact. Digital technologies such as transparent AI tools, electronic witnessing and automated cryo storage are becoming more commonplace and widely deployed in the reproductive health space. These can enable greater transparency and increased clinician-patient collaboration.

Harnessing the power of AI to augment IVF decisions

AI is going to impact more than just the patient experience. Fertility care is moving toward new areas of sophistication, which is being driven by data.

New tools and technologies in health in general and IVF specifically enable collection of vast amounts of data that either could not be collected before or was not good enough quality.

New transparent AI tools can take advantage of this data, with the ability to manage, interpret and truly make sense of it all. This is enabling standardisation of clinical protocols and improving accuracy and consistency in clinical decision making, regardless of the experience level of the embryologist.

The image-based nature of IVF has made it ripe for AI transformation. Collecting vast amounts of aggregated data, and training AI algorithms to identify specific biomarkers as an embryo develops, is giving embryologists a new level of insights into the quality of developing embryos that is not possible with human analysis alone.

With millions of data points collected and analysed during an IVF cycle, embryologists are being armed with rich AI-driven biological data and quality assessments to help them determine the most viable embryos.

AI-powered embryo quality selection tools are being deployed into clinics around the world. Utilising these tools to support clinical decisions along the IVF treatment journey, we may expect to see an overall improvement of IVF care outcomes, with patients requiring fewer IVF rounds to achieve a live birth.

The pandemic economy – what’s in store for IVF?

One of the biggest challenges the world is grappling with as we close 2022 is the post-pandemic economic crisis. However, it is unlikely the economic downturn will affect the fertility care market in the way it has other fields.

Since peoples’ desire to become parents is a fundamental need for many, prospective parents will prioritise IVF over anything else. These single-minded patients will be doing their homework on which fertility care provider is most likely to help them fulfil their dreams.

Fertility clinics will need to up their offerings to prove to their potential patients that they can get the job done. This is going to position clinics utilising advancing AI decision support tools ahead of the rest, since prospective parents who are tight on funds will want to make sure they are given the best chance of success.

Advancements in technology can provide hope to those who are invested in the IVF process. It will facilitate a lot of the changes that we need to see, including improved access, lower costs, improved patient experiences and more consistent and objective clinical decision making.

Based on patient demand, IVF professional need, and the new technologies entering the IVF lab, 2023 is poised to be a year in which we see the bar raised on the standard of care in this field.

For more info, visit fairtility.com.

Insight

Why advocacy-orientated CPD matters for the future of cardiology

Published

on

By Women As One

At the 2026 Alliance Annual Conference, Women As One presented a poster that asked a powerful question: What if continuing professional development (CPD) did more than teach clinical knowledge— and instead helped shape the future of the workforce itself?

For decades, professional education in medicine has focused primarily on what clinicians know and how they practice. That work remains essential.

But persistent gender gaps across cardiology—from leadership positions to research participation and speaking opportunities—demonstrate that knowledge alone is not enough to ensure equitable advancement.

To truly strengthen the field of cardiology, professional development must also support who clinicians become, the opportunities they access, and the voices that shape the future of cardiovascular medicine.

Our poster, More Than Education: Elevating Equity and Identity Through CPD, explores how a new model of advocacy-orientated CPD can help close these gaps.

Advocacy-orientated CPD expands the traditional model of professional education. In addition to building clinical expertise, it intentionally supports the structural elements that shape career advancement—mentorship, sponsorship, leadership development, visibility, and professional networks.

By integrating these elements into professional education, CPD can become a powerful engine for advancing equity—and ultimately improving patient care.

Why this matters

Gender inequities in medicine are not simply workforce issues. They influence research priorities, clinical trial representation, leadership decision-making, and ultimately the care patients receive.

When women clinicians have equitable opportunities to lead, research, and shape clinical practice, the entire healthcare system benefits.

Yet structural barriers remain. Women physicians often have less access to mentorship, sponsorship networks, and leadership pathways—factors that are critical for career advancement.

This is where advocacy-orientated CPD comes in.

By intentionally designing programs that foster mentorship, build leadership skills, create visibility, and support long-term professional growth, organizations can help ensure that the next generation of cardiovascular leaders reflects the diversity of the patients they serve.

Turning opportunity into impact

Since its founding, Women As One has supported thousands of women cardiologists across more than 100 countries, expanding access to mentorship, research opportunities, and leadership development.

Through programs like CLIMB, RISE, Mentorship Awards, and our global digital community, The Pulse, thousands of women cardiologists have gained mentorship, leadership training, and opportunities that accelerate their careers and expand their influence.

Today, the outcomes of these programs are shaping the field in tangible ways:

  • Women As One alumnae are leading clinical trials and advancing cardiovascular research
  • Clinicians supported through our programs are building registries, launching new care models, and expanding access to specialized care
  • Women cardiologists are gaining greater representation on speaker panels, advisory boards, and leadership pathways
  • A global community of more than 3,000 women cardiologists is strengthening collaboration, mentorship, and visibility across the profession

These outcomes demonstrate what becomes possible when professional development goes beyond traditional education to intentionally support leadership, identity, and community.

A call to the cardiovascular community

Advancing equity in cardiology is not the responsibility of one organization—it requires a collective effort across the entire ecosystem of clinicians, educators, institutions, and industry partners.

For women cardiologists, this means engaging in the programs, mentorship networks, and leadership opportunities that help shape the future of the field. Whether through CLIMB, RISE, research initiatives, or participation in The Pulse community, your involvement strengthens a growing movement dedicated to advancing women in cardiology.

For our partners and supporters, this work demonstrates the powerful impact that strategic investment in equity-focused professional development can have on the workforce and the patients we ultimately serve.

Together, we can redefine what professional development looks like in medicine—not just as a pathway for learning, but as a catalyst for leadership, opportunity, and lasting change.

Explore the poster

We invite you to explore the poster below (click here to download it) to learn more about the evidence, framework, and real-world impact behind this work—and to join us in continuing to expand what professional development can achieve for the future of cardiovascular medicine.

Learn more about Women As One at womenasone.org

Continue Reading

Opinion

What Maternal Mental Health Month reveals about where postpartum support actually breaks down

Published

on

By Morgan Rose, chief science officer at Ema, and Lauren Scocozza, vice president of product at Willow

May is Maternal Mental Health Month, and every year it surfaces a familiar set of statistics: 1 in 5 new mothers experiences postpartum depression or anxiety, most go unscreened, and the majority who are screened don’t receive adequate follow-up care.

The conversation is important. But the numbers obscure something that anyone who has worked in this space knows to be true: postpartum mental health distress rarely arrives with a label.

It arrives as exhaustion. As “I’m not sure I’m doing this right.”

As a question about supply, pumping, whether it’s okay to feel this disconnected from something you were supposed to love immediately.

Willow integrated Ema, AI built for women’s health, with the goal of closing the maternal care and data gap.

The pattern mentioned above appears consistently in Ema’s conversational data through the Willow app.

A mother reports mastitis symptoms.

Ema walks her through the clinical presentation, confirms she should keep pumping, and then she questions if she is using her pump correctly. In the same thread, within a few exchanges, she says she’s “feeling too sad.” Then: “I don’t know. I think I’m depressed. I am not enjoying my postpartum.”

She did not come to the app to talk about her mental health.

She came about a breast infection. The mental health disclosure came through the already-opened door.

The Weight Underneath the Technical Question

New motherhood involves an enormous amount of problem-solving at a time when cognitive and emotional reserves are depleted. The pump has to work. The baby has to eat. The body has to recover.

Work comes back. Sleep doesn’t. Feeding their babies requires skill, and the learning curve sits atop it all.

What Ema’s conversation data shows is that the emotional load of navigating these challenges is not separate from mental health. It is mental health.

When a mother writes, “I’m postpartum and overwhelmed and tired,” and then, in the same breath, asks about flange sizing, she is telling us what the postpartum experience actually feels like from the inside.

The technical question and the emotional state are one and the same.

Breastfeeding carries particular weight here.

The desire to breastfeed, the guilt when it doesn’t go as planned, and the identity questions that come with feeding choices are not peripheral to the postpartum mental health conversation.

In our conversations, women navigating supply concerns often reveal deeper anxieties: about whether they are good mothers, whether their bodies are “working,” and whether the difficulty they are experiencing means something about them.

These are the signals worth asking about.

What Screening Looks Like in Practice

Ema is trained on the Edinburgh Postnatal Depression Scale and is equipped to offer the EPDS when a conversation warrants it.

The value is being present for the moment when a woman is ready to name what she’s feeling.

That moment rarely comes as a direct request for mental health support. It comes when someone is already in a conversation about something else, and something shifts.

A woman dealing with mastitis says she feels sad. A woman worried about supply says she doesn’t feel like herself. A woman managing the logistics of going back to work with a wearable pump says she’s not sure she can keep up with it all — and the “it all” isn’t about the pump.

Ema is designed to hear that. She doesn’t stay on the clinical or technical track when the conversation moves. She follows the person.

And when the moment is right, she offers the screening as a natural next step.

In one exchange, a woman was offered the EPDS after disclosing depressive feelings. She declined.

Ema acknowledged that and asked if she wanted to talk about something else. That’s the right response. The offer was made without pressure. The door stays open.

Sometimes what matters most is that someone asked at all.

The Continuity Problem

One of the most persistent structural failures in maternal mental health care is fragmentation.

A woman sees her OB at six weeks postpartum for a brief screening. She may get a call from a nurse. She may be given a referral she never follows up on because she doesn’t have the capacity to navigate a new care relationship while managing a newborn.

The clinical touchpoints are too few, too far apart, and too often siloed from one another.

The postpartum period lasts far longer than the six-week checkup implies. Mental health symptoms can emerge weeks or months after delivery, shift in character over time, and interact with physical challenges in ways that don’t fit neatly into any single provider’s lane.

A lactation concern becomes an anxiety spiral. A supply drop triggers a grief response. A difficult return to work surfaces a postpartum depression that wasn’t fully recognized at six weeks.

Ema sits inside these moments because she’s embedded in the platform women are already using. She doesn’t require a separate appointment, a referral, or the cognitive bandwidth to seek out a new resource.

She’s in the Willow app that mom is already using multiple times a day to manage her pump.

When Ema identifies a woman who may need more support than she can provide, she routes to the right resource — whether that’s a SimpliFed lactation consultant for feeding-related concerns or a clinical professional for mental health follow-up.

The conversation leads to the handoff with someone who can do more.

What the Month of May Means for the Rest of the Year

Maternal Mental Health Month is a useful moment of attention. The awareness campaigns, the social media posts, and the statistics shared in newsletters matter.

But the gap in postpartum mental health care is not really an awareness problem.

Most people in the perinatal space and beyond know the statistics. The problem is access, timing, and continuity.

AI doesn’t close that gap on its own.

What it can do is be present in the spaces where women already are, at the times when they need something, and attentive enough to recognise that a conversation about a pump, a clogged duct, or a supply concern is also a conversation about how someone is doing.

The question behind the question is often the more important one.

For Willow, the conversation data Ema generates is a map of where mothers are struggling, what they reach for when they need help, and when they are ready to say more than they came to say.

That information, used well, shapes better resources, better onboarding, and a more connected experience across the full arc of the postpartum year and beyond.

Building the infrastructure to support maternal mental health is a year-round project.

Willow is doing one part of that, and the conversations happening on the Willow platform every day are evidence that women want support that meets them where they are… in their app, in their moment, without having to ask for it twice.

About the authors

Morgan Rose is Chief Science Officer at Ema, an AI platform for women’s health. Ema partners with healthcare organisations and femtech companies to deliver clinically grounded AI support across the perinatal journey.

Lauren Scocozza is the Vice President of Product at Willow Innovations, Inc. For women by women, Willow is building a maternal care platform to address the interconnected challenges of postpartum.

Continue Reading

Opinion

Femtech’s next chapter: Building a truly equal and comprehensive health tech category

Published

on

By Wolfgang Hackl, MD, CEO OncoGenomX, Allschwil, Switzerland

FemTech is moving from a promising niche to a foundational part of modern healthcare.

Over the next decade and beyond, its real promise will not only be better products, but a more equitable system: one where women’s health is treated as an equal area for innovation, investment, clinical care, and public policy.

That shift matters because women’s health has long been under-researched, underfunded, and too often managed through systems that were not designed with female biology and life stages in mind.

The opportunity now is to change that trajectory.

If stakeholders act deliberately, FemTech can become a category that improves outcomes, expands access, and creates measurable value across the HealthTech ecosystem.

From niche to infrastructure

The most important change ahead is a mindset shift. FemTech should no longer be seen as a narrow consumer segment focused only on logging symptoms.

It should be understood as health infrastructure spanning puberty, fertility, pregnancy, postpartum recovery, menopause, pelvic health, chronic disease, mental health, and long-term preventive care.

This broader framing creates a more durable market and a stronger social case. It also encourages innovation that serves people across the full life course, rather than only at highly visible moments.

In practical terms, this means building tools that are clinically relevant, integrated into care pathways, and designed to work for different populations and health systems.

What needs to change

For FemTech to become a truly equal healthcare category and a genuine societal priority, several layers need to move together.

First, the evidence base must deepen. More sex-disaggregated data, more women-inclusive clinical studies, and more research on conditions that disproportionately affect women are essential.

Without stronger evidence, product development, diagnosis, reimbursement, and clinical adoption all remain constrained.

Second, policy and regulation must mature. Privacy protections need to be strong enough to build trust in highly sensitive health data.

Regulatory pathways should be clear enough to help innovators bring safe, effective products to market without unnecessary delay.

Reimbursement frameworks also need to evolve so that useful digital tools are not limited to those who can pay out of pocket.

Third, healthcare systems must become more open to integration. The best FemTech products should not sit outside the care journey as standalone apps.

They should connect with clinicians, diagnostics, telehealth, and care coordination so that patients experience continuity rather than fragmentation.

Finally, society needs a broader cultural shift. Women’s health should be discussed as a mainstream public health and economic issue, not as a side topic or a private concern.

That means normalizing conversations around menopause, miscarriage, postpartum health, chronic pain, infertility, and long-term preventive care.

The role of each stakeholder

A healthier FemTech future depends on the full value chain.

Founders and product teams need to design for clinical relevance, usability, and trust. The strongest solutions will be those that solve real problems, use data responsibly, and fit into everyday life and care.

Investors can help by backing long-term value creation rather than only consumer growth. FemTech deserves capital that supports rigorous validation, regulatory readiness, and scalable business models.

Healthcare providers and systems play a critical role in adoption. By integrating FemTech into clinical workflows, they can reduce delays in care, improve monitoring, and make support more continuous and personalised.

Payers and insurers can accelerate access by recognising the downstream value of early intervention, prevention, and better self-management. Coverage decisions will strongly shape which innovations become standard practice.

Policymakers and regulators should create environments where safety, innovation, and privacy coexist. Clear standards and supportive reimbursement policy can make the difference between isolated success and category-wide growth.

Employers and public institutions also have a role. Women’s health affects productivity, retention, and long-term wellbeing, which means workplace benefits and public programs can help expand access and reduce inequity.

FemTech is not only “women for women.” It is “everyone to solve a health and social issue that has been ignored for far too long.”

When stakeholders across the value chain recognise women’s health as a shared responsibility, FemTech moves from a segmented category to a mainstream force for better outcomes, fairer access, and stronger social impact.

Why the upside is larger than the market

The benefit of getting this right is not only commercial.

Better women’s health tools can improve early detection, support self-management, reduce avoidable complications, and lower the burden on social and healthcare systems.

They can also help close persistent gaps in access and outcomes that affect families, workplaces, and economies.

For HealthTech innovators, this is an opportunity to build products that are both mission-driven and scalable. For health systems, it is a chance to improve care quality and efficiency. For society, it is a way to move women’s health from an afterthought to an equal priority.

Actions that will move the field forward

The right direction will not happen automatically. It requires deliberate action across the ecosystem.

  • Build products around real clinical needs, not only consumer engagement.
  • Invest in women-inclusive research and validation from the start.
  • Design privacy and governance into the product architecture.
  • Create reimbursement models that reward prevention and continuity.
  • Integrate FemTech into mainstream care pathways.
  • Expand education for clinicians, employers, and the public.
  • Expand the category to the invisible concerns to cover the full range of women’s health needs.

When these actions align, FemTech can mature into something larger than a market category. It can become a model for how health innovation should work: evidence-based, inclusive, trusted, and built to improve lives at scale.

A strong FemTech future is not just possible. It is a practical next step if the ecosystem chooses to treat women’s health as what it truly is: a core healthcare priority and a major driver of innovation.

Table: FemTech Focus Areas

FieldApproximate number of active solutions/companies
Reproductive health & fertility120+
Pregnancy & maternal care80+
Menstrual health60+
General women’s health & wellness50+
Diagnostics & monitoring45+
Menopause & perimenopause40+
Pelvic & uterine health30+
Chronic women’s health / integrated care30+
Sexual health & wellness25+

Legend: FemTech is becoming a multi-category healthcare layer. Reports also show that software/apps remain the largest product type overall, while reproductive health continues to dominate as an application area. Best-effort estimates based on category listings, company directories, and market reports, not audited totals.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.